(:ABMD)

Business Focus: N/A

Dec 21, 2022 09:00 am ET

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. Th

Dec 19, 2022 05:35 pm ET

Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400

NEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap 400 effective prior to the opening of trading on Thursday, December 22. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Abiomed in a deal expected to close soon pending final conditions.

Dec 06, 2022 11:07 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD

NEW YORK, Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Dec 05, 2022 02:24 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds APEN, ABMD, BNFT, and FRSH Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 5, 2022 /PRNewswire/ --

Dec 05, 2022 08:03 am ET

First Patients in the World Treated with Impella RP Flex with SmartAssist

Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their native heart. The patients were treated

Nov 29, 2022 10:35 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIMC, AGFS, BNFT, ABMD

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Nov 28, 2022 02:17 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds ABMD, BNFT, FRSH, and AIMC Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 28, 2022 /PRNewswire/ --

Nov 22, 2022 10:15 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIMC, ABMD, BNFT, LBC

NEW YORK, Nov. 22, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Nov 21, 2022 10:17 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds ABMD, BNFT, FRSH, and AIMC Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 21, 2022 /PRNewswire/ --

Nov 17, 2022 04:49 pm ET

INVESTOR ALERT: The M&A Class Action Firm Continues Investigating the Merger - ABMD, AGFS, AKUS, AIMC

NEW YORK, Nov. 17, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

Nov 17, 2022 04:23 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds LBC, AERC, AKUS, and ABMD Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 17, 2022 /PRNewswire/ --

Nov 16, 2022 12:24 pm ET

ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abiomed, Inc. (NasdaqGS: ABMD) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Abiomed will receive $380.00 in cash for each share of Abiomed that they own and a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. KSF is seeking to determine whether this consideration and the process that l

Nov 16, 2022 09:07 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIMC, ABMD, BNFT

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NASDAQ:...

Nov 15, 2022 04:17 pm ET

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SLDB, LFG, BNFT, ABMD

Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...

Nov 15, 2022 09:45 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ABMD, BNFT, OYST, VLDR

NEW YORK, Nov. 15, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Nov 14, 2022 04:17 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds ABMD, BNFT, FRSH, and AIMC Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 14, 2022 /PRNewswire/ --

Nov 10, 2022 08:20 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIMC, ABMD, BNFT, ATCO

Nov 08, 2022 04:31 pm ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIMC, ABMD, BNFT, ATCO

NEW YORK, Nov. 8, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Nov 08, 2022 12:17 pm ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD),

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...

Nov 07, 2022 03:42 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds ABMD, BNFT, FRSH, and AIMC Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 7, 2022 /PRNewswire/ --

Nov 03, 2022 03:56 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BNFT, ATCO, ABMD, AVEO

Nov 02, 2022 05:52 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATCO, ABMD, BNFT

NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Nov 01, 2022 10:10 pm ET

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of ABIOMED, Inc. - ABMD

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating ABIOMED, Inc. (ABMD), relating to its proposed acquisition by Johnson & Johnson. Under the terms of the tender offer, ABMD shareholders will receive $380.00 in cash per share they own. Click here for more information: https://www.monte

Nov 01, 2022 06:42 pm ET

ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD

Nov 01, 2022 05:53 pm ET

SHAREHOLDER ALERT: Weiss Law Investigates Abiomed, Inc.

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Abiomed, Inc. ("Abiomed" or the "Company") (NASDAQ: ABMD), in connection with its proposed tender offer by Johnson & Johnson (NYSE: JNJ). Under the tender offer, the Company's shareholders will receive $380.00 in cash, reflecting an enterprise value of approximately $16.6 billion, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $35.00 for each share of Abiomed common stock owned.

Nov 01, 2022 10:45 am ET

Thinking about buying stock in Atlas Corp, Unity Biotechnology, Abiomed, Tilray, or Pfizer?

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATCO, UBX, ABMD, TLRY, and PFE.

Nov 01, 2022 10:25 am ET

Shareholder Alert: Ademi LLP investigates whether ABIOMED, Inc. has obtained a Fair Price in its transaction with Johnson & Johnson

MILWAUKEE, Nov. 1, 2022 /PRNewswire/ -- Ademi LLP is investigating ABIOMED (NASDAQ: ABMD) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson.

Nov 01, 2022 07:33 am ET

ABMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ABIOMED, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ABIOMED, Inc. (NASDAQ: ABMD) to Johnson & Johnson is fair to ABIOMED shareholders. Under the terms of the agreement, ABIOMED shareholders would receive $380.00 per share in cash and a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved.

Nov 01, 2022 07:00 am ET

Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022.

Nov 01, 2022 06:30 am ET

Johnson & Johnson to Acquire Abiomed

Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, and Abiomed (NASDAQ: ABMD), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.00 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. Abiomed shareholders will also receive a non-tradeable contingent value right (

Oct 31, 2022 08:02 am ET

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed (Nasdaq: ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA’s highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the internal jugular (IJ) vein, which enables patient mobility, and

Oct 26, 2022 08:02 am ET

Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare

Abiomed (Nasdaq: ABMD) announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian cardiovascular patients. Data from a subgroup analysis of 93 non-Caucasian high-risk PCI patients enrolled in the

Oct 24, 2022 12:00 pm ET

MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization that helps military Veterans transition and gain employment at Medical Technology and Life Science companies. This announcement is being made today during the Plenary Luncheon at AdvaMed’s

Oct 20, 2022 10:24 am ET

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

Abiomed (Nasdaq: ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for

Oct 17, 2022 07:58 am ET

U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath

The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed (Nasdaq: ABMD) for its Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement of Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr. As a result of its smaller size and other t

Oct 13, 2022 08:02 am ET

Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support

An analysis of more than 2,000 patients from a large U.S. real-world database finds that patients who underwent a non-emergent high-risk PCI with the Impella heart pump (n=1,447) had significantly improved survival, reduced myocardial infarction, reduced cardiogenic shock after PCI and shorter length of stay tha

Oct 13, 2022 07:00 am ET

Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Tuesday, November 1, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trap

Sep 20, 2022 08:02 am ET

Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

Abiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis. This study is an update to a 2020 interim analysis and was announced at the

Sep 19, 2022 08:02 am ET

Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%

Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter

Sep 17, 2022 09:02 am ET

Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in patients who received left ventr

Sep 16, 2022 08:03 am ET

FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock patients.

Sep 13, 2022 08:02 am ET

TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery

Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the

Aug 16, 2022 08:02 am ET

Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

Abiomed (Nasdaq: ABMD) announces the results of the Restore EF study demonstrate Impella-supported high-risk percutaneous coronary intervention (PCI) leads to significant improvements in left ventricular ejection fraction (LVEF), angina symptoms and heart failure symptom

Aug 04, 2022 07:00 am ET

ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*

ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022.

Jul 14, 2022 07:00 am ET

Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Thursday, August 4, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp,

Jun 14, 2022 04:30 pm ET

Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps

Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m. ET. The event will include presentations from heart failure specialists, Dr. David D’Alessandro, Surgical Director, Heart Transplantation and

May 31, 2022 07:00 am ET

Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference

Abiomed, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present (live) at the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022 at 2:00pm CT.

May 18, 2022 08:03 am ET

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

Abiomed (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock (A

Apr 28, 2022 07:00 am ET

Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year

ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022.

Apr 26, 2022 08:02 am ET

World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump

Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump’s U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS). The first imp

Apr 08, 2022 07:00 am ET

Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, April 28, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp,

Apr 06, 2022 08:04 am ET

First Patient in Japan Treated with Impella 5.5 with SmartAssist

The versatility and innovation of Abiomed’s (NASDAQ: ABMD)

Mar 21, 2022 07:00 am ET

Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French

Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on Impella ECP on March 29, 2022 from 4:00 p.m. – 5:00 p.m. EDT. The event will include presentations from circulatory support leader, Dr. Amir Kaki, interventional cardiologist and director of mechanical circulatory support at Ascension St. John Hospital in Detroit and Abio

Feb 08, 2022 04:05 pm ET

Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference (virtual) on Thursday, February 17, 2022 at 10:40am.

Feb 03, 2022 07:00 am ET

Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year

ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021.

Jan 14, 2022 07:00 am ET

Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, February 3, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Tra

Jan 12, 2022 08:03 am ET

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed (NASDAQ: ABMD) announces the successful results of the first-in-human early feasibility study of the preCARDIA system. The preCARDIA system is designed to improve decongestion in acutely decompensated heart failure (ADHF) patients by intermittently occluding the superior vena cava. The results of the study published this week in the journal

Jan 10, 2022 08:02 am ET

Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

Regulators in three countries have granted approvals to Impella surgical products, as Abiomed (NASDAQ: ABMD) continues to execute its strategy for sustainable growth with new products, new indications and new geographies. In the United States, the Food and Drug Administration (FDA) has granted an Early Feasibility Study (EFS) Investigational Device Exemption (

Dec 29, 2021 07:00 am ET

Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference (virtual) on Wednesday, January 12, 2022, at 1:30pm ET.

Nov 18, 2021 07:00 am ET

Abiomed to Present at Upcoming Investor Conferences

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens Annual Investment Conference 2021 on Wednesday, December 1, 2021, at 3:00pm ET and at the Piper Sandler Virtual Healthcare Confere

Nov 04, 2021 08:05 am ET

Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes

The final results of the PROTECT III and Restore EF prospective studies demonstrate improved outcomes for high-risk PCI patients with the use of Impella heart

Nov 03, 2021 08:02 am ET

Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines

The 2021 guidelines of the European Society of Cardiology (ESC) for treatment of acute heart failure patients, including patients in cardiogenic shock, raise the recommendation level for short-term mechanical circulatory support systems such as

Nov 01, 2021 07:58 am ET

TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology

The robust, high-quality data and clinical studies supporting the use of Abiomed's (NASDAQ:ABMD)

Oct 28, 2021 07:00 am ET

Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended September 30, 2021.

Oct 07, 2021 07:00 am ET

Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, October 28, 2021, the Company will release financial results for the second quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, October 28, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Tr

Aug 18, 2021 08:02 am ET

FDA Grants Breakthrough Device Designation to Impella ECP, the World’s Smallest Heart Pump

The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD)

Aug 04, 2021 04:15 pm ET

Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended June 30, 2021.

Jul 15, 2021 07:00 am ET

Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 5, 2021, the Company will release financial results for the first quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, August 5, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp,

Jun 29, 2021 08:03 am ET

FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure

Abiomed’s (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart failure for up to 14 days.

Jun 01, 2021 08:03 am ET

Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients

Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed’s product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures

May 25, 2021 07:00 am ET

Abiomed to Present at Upcoming Investor Conferences

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at William Blair’s 41st Annual Growth Stock Conference (virtual) on Tuesday, June 1st at 4:40pm CT and the Jefferies Virtual Healthcare C

Apr 29, 2021 07:00 am ET

Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record fourth quarter fiscal 2021 revenue of $241.2 million compared to revenue of $206.7 million for the same period of fiscal 2020, driven by a record number of patients supported. For fiscal year 2021, total revenue was $847.5 million, up 1% compared to revenue of $840.9 million, and operating income was $229.6 million compared to operating income of $249.2 million in fiscal year 2020.

Apr 28, 2021 03:57 pm ET

Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella

The final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an

Apr 28, 2021 08:03 am ET

Dr. Paula A. Johnson Joins Abiomed Board of Directors

Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors.

Apr 15, 2021 08:03 am ET

First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella

Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a

Apr 08, 2021 07:00 am ET

Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, April 29, 2021, the Company will release financial results for the fourth quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, April 29, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief F

Mar 04, 2021 09:00 am ET

MEDCERT Enables the Use of the Single Access Procedure with Impella CP Introducer Sheaths in Europe

Following consultation with its notified body, MEDCERT GmbH, Abiomed is introducing the single access procedure with Impella CP introducer sheaths for the treatment of heart disease in Europe.

Feb 17, 2021 08:03 am ET

Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors

Abiomed (NASDAQ: ABMD) announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors, effective immediately. Dr. Rolle will serve as a member of the Governance and Nominating Committee and Regulatory and Compliance Committee of the board. With the appointment of Dr. Rolle, the board now comprises of eight active directors.

Feb 17, 2021 07:00 am ET

Abiomed to Present at Upcoming Investor Conferences

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the SVB Leerink 10th Annual Global Healthcare Conference (virtual) on Wednesday, February 24th at 8:40am ET and the Raymond James 2021

Jan 29, 2021 09:03 am ET

Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist

Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with

Jan 28, 2021 07:00 am ET

Abiomed Announces Q3 FY 2021 Record Revenue of $232 Million, up 5% Year Over Year, With 31% Operating Margin

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record revenue in the third quarter fiscal 2021 of $231.7 million, a year over year increase of 5% compared to Q3 fiscal year 2020 despite the negative impact of COVID-19. Operating income was $71.4 million up 2%, compared to $70.3 million in the same period of fiscal 2020.

Jan 14, 2021 07:00 am ET

Abiomed Third Quarter Fiscal 2021 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, January 28, 2021, the Company will release financial results for the third quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, January 28, 2021 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief

Jan 07, 2021 08:03 am ET

Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1,000 Patents

Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed’s robust intellectual property portfolio protects its current and future pump and catheter designs, along with other product components such as motors, cannulas, sensors, software, and access devices. The portfolio also pr

Dec 29, 2020 07:00 am ET

Abiomed to Present at the 39th Annual J.P. Morgan Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference (virtual) on Tuesday, January 12, 2021 at 5:20pm EST.

Dec 21, 2020 08:05 am ET

First Patients, Including a COVID-19 Patient, Treated with Abiomed’s Innovative ECMO Technology

Abiomed (NASDAQ: ABMD) announces the first two patients in the world have been treated with the Abi

Dec 15, 2020 08:03 am ET

Two Milestones Achieved Toward Small Bore Access with Impella

Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pump has completed the first stage in its U.S. Food and Drug Administration (FDA) early feasibility study (EFS) and the FDA has granted 510(k) clearance to the Impella XR sheath.

Nov 25, 2020 07:00 am ET

Abiomed to Hold Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020 at 8:30am ET.

Nov 11, 2020 07:00 am ET

Abiomed to Hold Fireside Chat at the Stephens Annual Investment Conference 2020

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens Annual Investment Conference 2020 (virtual) on Wednesday, November 18, 2020 at 9:00am ET.

Nov 05, 2020 08:00 am ET

First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Heart Pump Designed for Surgeons

Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the

Oct 29, 2020 04:01 pm ET

Axogen, Inc. Reports Third Quarter 2020 Financial Results

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended September 30, 2020....

Oct 29, 2020 07:00 am ET

Abiomed Announces Q2 FY 2021 Revenue of $210 Million, Up 27% Over Q1 FY 2021 and Up 2% Over Q2 FY 2020 With 29.2% Operating Margin

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported second quarter fiscal 2021 revenue of $209.8 million, a sequential increase of 27% compared to Q1 fiscal year 2021 and a year over year increase of 2% compared to Q2 fiscal year 2020 despite the negative impact of COVID-19. Operating income was $61.3 million up 2%, compared to $60.2 million in the same period of fiscal 2020.

Oct 28, 2020 08:03 am ET

First Patients Treated with the World’s Smallest Heart Pump, the 9Fr Impella ECP

Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 French (Fr) (3 millimeters) in diameter upon insertion and removal from the body. While in the heart, it expands while supporting the heart’s pumping function, pro

Oct 26, 2020 07:55 am ET

FDA Grants 510(k) Clearance for Abiomed’s Innovative Cardiopulmonary Support Technology

The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the

Oct 16, 2020 08:05 am ET

Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP

Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of

Oct 16, 2020 07:05 am ET

Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women

Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI. The findings were presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation.

Oct 15, 2020 08:30 am ET

Abiomed to Host a Virtual Meeting to Discuss New Clinical Data Presented at TCT Connect

Abiomed, Inc. (NASDAQ: ABMD) announced it will host a virtual investor meeting on Tuesday, October 20, 2020 at 8:00 a.m. EDT to review new clinical data presented at

Oct 15, 2020 08:05 am ET

Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes

Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and repeat procedures) when

Oct 14, 2020 08:05 am ET

Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves Left Ventricular Ejection Fraction

The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella-supported high-risk PCI, is associated with significant improvement of left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms at follow up. The interim analysis was presented toda

Oct 08, 2020 05:00 pm ET

Abiomed Second Quarter Fiscal 2021 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, October 29, 2020, the Company will release financial results for the second quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, October 29, 2020 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chie

Oct 08, 2020 08:00 am ET

TCT Connect to Highlight How Impella Enables Improved Outcomes for High-Risk PCI, Cardiogenic Shock and Right Heart Failure Patients

The benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients will be highlighted at

Sep 30, 2020 04:01 pm ET

Axogen, Inc. Appoints Paul G. Thomas to Board of Directors

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Paul G. Thomas has been appointed to its Board of Directors, effective...

Sep 14, 2020 07:00 am ET

Abiomed to Hold Fireside Chat at the Raymond James North American Equities Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Raymond James North American Equities Conference (virtual) on Thursday, September 17th, 2020 at 10:30 am ET.

Sep 08, 2020 07:00 am ET

Abiomed to Hold Fireside Chat at the 18th Annual Morgan Stanley Global Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference (virtual) on Tuesday, September 15th, 2020 at 2:45pm ET.

Aug 06, 2020 07:00 am ET

Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported first quarter fiscal 2021 revenue of $164.9 million compared to revenue of $207.7 million for the same period of fiscal 2020 despite a negative impact from the COVID-19 pandemic. The company delivered sequential revenue and patient growth each month within the quarter, with June up 4% versus prior year. Operating income was $34.1 million down 44%, compared to $60.7 million in the same period of fiscal 2020.

Aug 04, 2020 07:00 am ET

FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients

The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing

Jul 30, 2020 08:00 am ET

Large Multi-Center Study in Japan Finds High Survival Rates with Use of Impella Heart Pump

A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump finds use of Impella is associated with a 77% survival rate at 30 days in AMI cardiogenic shock patients. The historic survival rate for cardiogenic shock is approximately 50%. The study, conducted with oversight by 10 Japanese professional societies, inc

Jul 16, 2020 07:00 am ET

Abiomed First Quarter Fiscal 2021 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 6, 2020, the Company will release financial results for the first quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, August 6, 2020 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Fin

Jul 16, 2020 07:00 am ET

FDA Approves Data Streaming from the Impella Console, Setting the Stage for Artificial Intelligence Algorithms to Further Improve Patient Outcomes

The United States Food and Drug Administration (FDA) has approved one-way digital data streaming during patient support from Abiomed's (NASDAQ: ABMD) Automated Impella Controller (AIC), the external console used with

Jul 02, 2020 09:00 am ET

MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent $150 million private equity and debt financings,...

Jul 01, 2020 07:00 am ET

Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist

The first published United States experience of patients who received Abiomed’s newest heart pump,

Jun 16, 2020 07:00 am ET

Abiomed Launches Virtual Physician Education Program, CAMP PCI, to Improve High-Risk PCI Patient Outcomes

Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI, which stands for Coronary Ar

Jun 15, 2020 07:00 am ET

Abiomed Appoints New Chief Medical Officer Charles Simonton, M.D.

Abiomed (Nasdaq: ABMD), maker of the Impella heart pump, announced today it has appointed Charles (Chuck) Simonton, M.D., a

Jun 05, 2020 09:41 am ET

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump

Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP™ heart pump. Impella ECP, which stands for expandable cardiac power, will be studied in high-risk percutaneous

Jun 05, 2020 07:00 am ET

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump

Jun 03, 2020 04:30 pm ET

Abiomed to Hold Fireside Chat at the William Blair 40th Annual Growth Stock Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the William Blair 40th Annual Growth Stock Conference (virtual) on Wednesday, June 10, 2020 at 1:20pm CT.

Jun 01, 2020 07:00 am ET

FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure

The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE).

May 27, 2020 04:30 pm ET

Abiomed to Hold Fireside Chat at Jefferies Virtual Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:00am.

May 20, 2020 07:00 am ET

Abiomed to Host Virtual Clinical Data and Innovation Day

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that it will host a Virtual Investor Day covering Clinical Data & Innovation on May 27, 2020 from 8:30 a.m. – 12:00 p.m. EDT. The event will include presentations from members of Abiomed’s senior management team and 5 Physicians Experts providing

May 19, 2020 09:32 am ET

PROTECT III Study Shows Placing Impella Prior to High-Risk PCI is Associated with Lower Mortality Compared to Bailout PCI

Data from more than 1,000 patients presented during the virtual 2020 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions demonstrates Impella reduced in-hospital mortality when placed before a non-emergent percutaneous coronary interven

Apr 30, 2020 07:00 am ET

Abiomed Announces Q4 FY 2020 Revenue of $207 Million and 28.1% Operating Margin

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported fourth quarter fiscal 2020 revenue of $206.7 million compared to revenue of $207.1 million for the same period of fiscal 2019. For fiscal year 2020, total revenue was $840.9 million, up 9% compared to revenue of $769.4

Apr 29, 2020 07:29 pm ET

Abiomed Expands Product Portfolio with Acquisition of Cardiopulmonary Support Technology (ECMO) to Improve Outcomes for Patients

Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal me

Apr 10, 2020 07:00 am ET

Abiomed Fourth Quarter Fiscal 2020 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, April 30, 2020, the Company will release financial results for the fourth quarter of fiscal 2020. The Company will host a conference call to discuss the results on Thursday, April 30, 2020, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief F

Mar 25, 2020 07:05 am ET

Abiomed’s Response to the COVID-19 Pandemic

Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, is taking a number of steps to aid the global medical commun

Mar 04, 2020 07:05 am ET

Study of 21,848 High-Risk PCI Patients Demonstrates Lower Risk of Death and Complications in Patients who Receive PVADs (Impella)

A study of 21,848 non-emergent, high-risk patients who underwent percutaneous coronary intervention (PCI) with percutaneous ventricular assist devices (PVADs), including Impella, demonstrates the PVAD patients had a lower rate of mortality and complications than patients who underwent PCI with intra-aortic balloon pumps (IABPs). The study, by Al-khadra,

Feb 06, 2020 07:00 am ET

Abiomed Announces Q3 FY 2020 Revenue of $222 Million and 31.7% Operating Margin

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported third quarter fiscal 2020 revenue of $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019. Operating income was $70.3 million, up 13%, compared to $62.4 million in the same perio

Jan 13, 2020 07:00 am ET

Abiomed Announces Preliminary Q3 FY 2020 Revenue of $222 Million, up 10% Over Prior Year

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported preliminary, unaudited, third quarter fiscal 2020 revenue of approximately $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019.

Dec 30, 2019 07:00 am ET

Abiomed to Present at the 38th Annual J.P. Morgan Healthcare Conference

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 12:00 p.m. PST / 3:00 p.m. EST. The conference will be held at the Westin S

Dec 16, 2019 08:05 am ET

First Patient Enrolls in STEMI DTU Randomized Controlled FDA Trial; Study Aims to Further Demonstrate Impella’s Safety and Effectiveness

Abiomed (NASDAQ: ABMD) announces initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial (RCT), which will explore whether unloading the heart’s left ventricle for 30 minutes with an

Dec 16, 2019 07:58 am ET

Large Randomized Controlled Trial Aims to Curb Rising Epidemic of Heart Failure

A pivotal, multi-center clinical trial to explore a promising new therapy to reduce heart failure rates by changing the way heart attack patients are treated is now underway. The first patient has enrolled in the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial. The first enrollment took place at

Nov 27, 2019 07:00 am ET

Abiomed to Present at the 31st Annual Piper Jaffray Healthcare Conference

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 3:00pm ET. The conference will be held at the Lotte New York Palace, New York, NY.

Nov 19, 2019 01:11 pm ET

Abiomed Medical Office Completes Review of Observational Analysis of Impella Presented at AHA

Abiomed (NASDAQ: ABMD) is committed to improving patient outcomes by performing FDA studies and post-market surveillance, collecting real-world evidence and identifying and sharing best practices.

Nov 14, 2019 09:59 am ET

Clinical Review Demonstrates Cost-Effectiveness of Impella in High-Risk PCI and Cardiogenic Shock

To mark the five year anniversary of the study by Stretch, et al., on cost and outcomes trends for short-term mechanical circulatory support,

Oct 31, 2019 07:02 am ET

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

Three cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and

Oct 31, 2019 07:00 am ET

Abiomed Announces Q2 FY 2020 Revenue of $205 Million and 29.4% Operating Margin

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2020 revenue of $205.0 million, an increase of 13% compared to revenue of $181.8 million for the same period of fiscal 2019. Operating income was $60.2 million, up 20%, compared to $50.3 million in

Oct 26, 2019 09:15 am ET

CORRECTING and REPLACING CAPTION FDA Post Approval Study Demonstrates Timely Identification of Right Heart Failure and Early Use of Impella RP Leads to Higher Survival

Please replace the caption for release dated October 25, 2019 with the accompanying corrected caption.

Oct 25, 2019 09:55 am ET

CORRECTING and REPLACING GRAPHIC FDA Post Approval Study Demonstrates Timely Identification of Right Heart Failure and Early Use of Impella RP Leads to Higher Survival

Please replace the graphic with the accompanying corrected graphic, which corrects a date on the graphic to read “Sep 2017.”

Oct 25, 2019 08:00 am ET

FDA Post Approval Study Demonstrates Timely Identification of Right Heart Failure and Early Use of Impella RP Leads to Higher Survival

Nearly two years of real-world outcomes data on Abiomed’s (NASDAQ: ABMD) Impella RP heart pump shows that when physician

Oct 10, 2019 03:55 pm ET

Abiomed Second Quarter Fiscal 2020 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, October 31, 2019, the Company will release financial results for the second quarter of fiscal 2020. The Company will host a conference call to discuss the results on Thursday, October 31, 2019, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Of

Oct 07, 2019 10:40 am ET

MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abiomed, Inc. (“Abiomed” or “the Company”) (NASDAQ:

Oct 07, 2019 09:40 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABMD, EVH, WTRH and MYGN

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Oct 07, 2019 08:00 am ET

Abiomed Announces 1,000th Patient Treated with Impella in Japan

Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, announces the 1,000th patient has been treated with the Impella heart pump in Japan. The Impella 2.5 and Impella 5.0 heart pumps are approved for the treatment of drug-resistant acute heart failure and are the first and only percutaneous temporary ventricular support devices Pharmaceu

Oct 06, 2019 02:30 pm ET

ROSEN, A LEADING LAW FIRM, Reminds Abiomed, Inc. Investors of Important October 7th Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ABMD

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abiomed, Inc. (NASDAQ: ABMD) from January 31, 2019 through July 31, 2019, inclusive (the “Class Period”) of the important October 7, 2019 lead plaintiff...

Oct 04, 2019 03:00 pm ET

SHAREHOLDER ALERT - Abiomed, Inc. (ABMD) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 7, 2019

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abiomed, Inc. (“Abiomed” or the Company”) (NASDAQ: ABMD) and certain of its officers, on behalf of shareholders who...

Oct 04, 2019 09:02 am ET

ABIOMED DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In ABIOMED, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - October 4, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ABIOMED, Inc. (NASDAQ: ABMD) ("ABIOMED" or the "Company")of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Oct 03, 2019 11:00 am ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Abiomed, Inc.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 7, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Abiomed, Inc. (“Abiomed” or the “Company”) (NASDAQ: ABMD) investors who purchased...

Oct 03, 2019 10:58 am ET

ABIOMED SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In ABIOMED, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - October 3, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ABIOMED, Inc. (NASDAQ: ABMD) ("ABIOMED" or the "Company") of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Oct 03, 2019 10:52 am ET

Zhang Investor Law Reminds Investors of October 7 Deadline in Securities Class Action Lawsuit Against Abiomed, Inc. – ABMD

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Abiomed, Inc. (NASDAQ: ABMD) from January 31, 2019 through July 31, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover...

Oct 03, 2019 10:26 am ET

CLASS ACTION UPDATE for ABMD, TXT, MDP and FTCH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...

Oct 02, 2019 12:02 pm ET

ABIOMED DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In ABIOMED, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - October 2, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ABIOMED, Inc. (NASDAQ: ABMD) ("ABIOMED" or the "Company") of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Oct 02, 2019 10:12 am ET

CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in TWOU, CURLF, and ABMD of Filing Deadlines

Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of TWOU, CURLF, and ABMD. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...

Oct 01, 2019 07:43 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ABIOMED, Inc. of Class Action Lawsuit and Upcoming Deadline – ABMD

Pomerantz LLP announces that a class action lawsuit has been filed against ABIOMED, Inc. (“ABIOMED” or the “Company”) (NASDAQ: ABMD) and certain of its officers. The class action, filed in United States District Court, for the Southern District...

Oct 01, 2019 11:00 am ET

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Abiomed, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming October 7, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Abiomed, Inc. (“Abiomed” or the “Company”) (NASDAQ: ABMD)...

Sep 30, 2019 07:45 pm ET

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Abiomed, Inc. Investors of Important October 7th Deadline in Securities Class Action – ABMD

Sep 27, 2019 11:35 pm ET

ABIOMED DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Abiomed, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - September 27, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abiomed, Inc. (NASDAQ: ABMD) ("Abiomed" or the "Company") of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Sep 27, 2019 03:00 pm ET

SHAREHOLDER ALERT - Abiomed, Inc. (ABMD) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 7, 2019

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abiomed, Inc. (“Abiomed” or the Company”) (NASDAQ: ABMD) and certain of its officers, on behalf of shareholders who...

Sep 27, 2019 08:05 am ET

Study Demonstrates Early Use of Impella Can Increase Survival in Cardiogenic Shock; Escalation Protocols Initiated

Data presented today from the National Cardiogenic Shock Initiative Study (NCSI) on 250 consecutive AMI cardiogenic shock (AMICS) patients from 49 sites demonstrates 72% survival at discharge with 98% native heart recovery. The patients were treated with the NCSI protocol, which includes placing

Sep 26, 2019 11:00 am ET

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Abiomed, Inc.

Sep 26, 2019 10:30 am ET

PROTECT III Presented at TCT 2019 – Clinical Data Demonstrates Protected PCI with Impella is Associated with Improved Outcomes

Abiomed (NASDAQ: ABMD) announces the results of PROTECT III, the ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.5 and Impella CP in high-risk PCI. PROTECT III follows the PROTECT II Randomized Controlled Trial (RCT).

Sep 25, 2019 03:54 pm ET

ABMD NOTICE: Zhang Investor Law Reminds Investors of October 7 Deadline in Securities Class Action Lawsuit Against Abiomed, Inc. – ABMD

Sep 25, 2019 02:55 pm ET

Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against ABIOMED, Inc. (ABMD) and October 7 Deadline

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against ABIOMED, Inc. (“ABIOMED” or the “Company”) (NASDAQ: ABMD), and certain other defendants, related to alleged violations of federal securities laws

Sep 25, 2019 07:05 am ET

Abiomed Receives FDA PMA Approval for Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for safety and efficacy in the therapy of cardiogenic shock for up to 14 days.

Sep 24, 2019 03:46 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ABIOMED, Inc. of Class Action Lawsuit and Upcoming Deadline – ABMD

Sep 24, 2019 11:26 am ET

INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in JE, ABMD, and CURLF of Filing Deadlines

Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of JE, ABMD, and CURLF. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...

Sep 24, 2019 09:50 am ET

CLASS ACTION UPDATE for GNLN, ABMD, TWOU and NTAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 23, 2019 11:05 pm ET

ABIOMED DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Abiomed, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - September 23, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abiomed, Inc. (NASDAQ: ABMD) ("Abiomed" or the "Company") of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Sep 23, 2019 06:10 pm ET

ABMD LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Abiomed, Inc. Investors of Important October 7th Deadline in Securities Class Action – ABMD

Sep 23, 2019 11:00 am ET

DEADLINE ALERT for CURLF, ABMD, NTAP, and PS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Sep 23, 2019 10:40 am ET

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. (“Abiomed” or “the Company”) (NASDAQ: ABMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act...

Sep 23, 2019 08:55 am ET

Highest Court in Germany Affirms Strength of Abiomed’s Patents

The highest court in Germany, the Federal Court of Justice, recently ruled in favor of Abiomed (NASDAQ: ABMD) in a patent challenge filed by Thoratec in 2015 and validated the strengths of Abiomed’s Impella-related patents.

Sep 20, 2019 03:00 pm ET

Class Actions - ABMD, IFF & GVA - Bronstein, Gewirtz & Grossman, LLC

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Sep 19, 2019 09:44 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VNTR, NGHC, ABMD and DXC

Sep 18, 2019 09:38 am ET

CLASS ACTION UPDATE for GNLN, ABMD, IFF and NTAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 17, 2019 08:48 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ABIOMED, Inc. of Class Action Lawsuit and Upcoming Deadline – ABMD

Sep 17, 2019 05:37 pm ET

Lifshitz & Miller LLP Announces Investigation of Abiomed, Inc., ADTRAN, Inc., AmTrust Financial Services, Inc., Impinj, Inc., MBIA Inc., Sundial Growers, Inc., and Tandy Leather Factory, Inc.

NEW YORK, Sept. 17, 2019 /PRNewswire/ --

Sep 17, 2019 01:27 pm ET

CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in ABMD, NFLX, and CARB of Filing Deadlines

Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ABMD, NFLX, and CARB. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...

Sep 17, 2019 10:54 am ET

CLASS ACTION UPDATE for ABMD, IFF, MGNX and CADE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 17, 2019 09:39 am ET

CLASS ACTION UPDATE for NGHC, ABMD, IFF and MGNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 17, 2019 08:35 am ET

Abiomed to Highlight Importance of Optimal PCI Treatment to Improve Outcomes for High-Risk Patients at TCT 2019

Abiomed (NASDAQ:ABMD) will highlight the benefits of complete revascularization with Protected PCI and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients at the 31st Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco from September 25-29. During the conference, Abiomed will al

Sep 16, 2019 11:15 am ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Sep 16, 2019 09:47 am ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In ABIOMED, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ABIOMED, Inc. ("ABIOMED" or the "Company")(NASDAQ:ABMD) of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...

Sep 13, 2019 03:00 pm ET

L Brands, Inc. (LB), GTT Communications, Inc. (GTT) & Abiomed, Inc. (ABMD) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC

Sep 12, 2019 04:50 pm ET

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Abiomed, Inc. Investors of Important October 7th Deadline in Securities Class Action – ABMD

Sep 12, 2019 02:24 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ABIOMED, Inc. of Class Action Lawsuit and Upcoming Deadline – ABMD

Sep 12, 2019 09:24 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NGHC, GTT, ABMD and CVS

Sep 11, 2019 11:51 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Abiomed, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abiomed, Inc. ("Abiomed" or the "Company") (NASDAQ:ABMD) of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...

Sep 10, 2019 09:34 am ET

CLASS ACTION UPDATE for LB, CARB, ABMD and GVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 09, 2019 01:00 pm ET

TWOU, VAL, and ABMD CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in TWOU, VAL, and ABMD of Filing Deadlines

Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of TWOU, VAL, and ABMD. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...

Sep 07, 2019 02:00 pm ET

ROSEN, A LEADING LAW FIRM, Reminds Abiomed, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ABMD

Sep 05, 2019 03:00 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ABIOMED, Inc. of Class Action Lawsuit and Upcoming Deadline – ABMD

Sep 04, 2019 03:00 pm ET

SHAREHOLDER ALERT - Abiomed, Inc. (ABMD) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 7, 2019

Sep 04, 2019 12:40 pm ET

JE, ABMD, NTAP, CTST CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in JE, ABMD, NTAP, and CTST of Filing Deadlines

Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of JE, ABMD, NTAP, and CTST. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A...

Sep 04, 2019 09:41 am ET

CLASS ACTION UPDATE for JE, CURLF, ABMD and TWOU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sep 03, 2019 12:59 pm ET

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Sep 03, 2019 10:20 am ET

ABMD SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Abiomed, Inc. – ABMD

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Abiomed, Inc. (NASDAQ: ABMD) from January 31, 2019 through July 31, 2019, inclusive (the “Class Period”). The lawsuit seeks to...

Sep 03, 2019 07:00 am ET

Abiomed to Present at the Morgan Stanley Global Healthcare Conference

Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 9:55am EDT. The conference will be held at the Grand Hyatt, New York, NY.

Aug 31, 2019 02:31 pm ET

ROSEN, A HIGHLY RANKED LAW FIRM, Reminds Abiomed, Inc. Investors of Important Deadline in Securities Class Action – ABMD

Aug 29, 2019 01:05 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ABIOMED, Inc. of Class Action Lawsuit and Upcoming Deadline – ABMD

Aug 29, 2019 11:12 am ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In ABIOMED, Inc. To Contact The Firm

Aug 28, 2019 09:27 am ET

CLASS ACTION UPDATE for NFLX, ABMD, IFF and NTAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Aug 27, 2019 11:30 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Abiomed, Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - August 27, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abiomed, Inc. (NASDAQ: ABMD) ("Abiomed" or the "Company") of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

You are here

(:ABMD)

Business Focus: N/A